Ambrx Biopharma (AMAM) announced the appointment of Renu Vaish, M.Sc., as Chief Regulatory Officer. Vaish will be responsible for overseeing and designing the Company’s global regulatory strategy and will report to the Company’s President and Chief Executive Officer, Daniel O’Connor. Most recently, Vaish served as the Senior Vice President, Regulatory Affairs at SpringWorks Therapeutics (SWTX).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AMAM:
- Adobe upgraded, Salesforce downgraded: Wall Street’s top analyst calls
- Ambrx Biopharma initiated with an Outperform at RBC Capital
- Ambrx to Present Preliminary ARX517 First-in-Human Safety, Efficacy, and Pharmacokinetics Data at ESMO 2023
- Ambrx Biopharma announces FDA granted Fast Track designation to ARX517
- FDA Grants Fast Track Designation for Ambrx’s ARX517 for the Treatment of Metastatic Castration-Resistant Prostate Cancer